Parkinson’s UK funding research into drug that could slow Parkinson’s progression
The £2.9m phase 2 trial of a drug that could slow the progression of conditions like Parkinson's will be funded by the Parkinson's Virtual Biotech, our international drug discovery and development programme.
Parkinson’s UK and Parkinson’s Foundation partner up to speed up the search for new treatments
Over the next 3 years, the US-based Parkinson’s Foundation will invest a minimum of $3m (over £2.4m) into the Parkinson’s Virtual Biotech, our international drug discovery and development programme.
Disappointing results from trials of vaccines for Parkinson’s, but hope for the future
2 clinical trials aiming to reduce the clumps of troublesome alpha-synuclein to protect brain cells have, so far, failed to show a clear benefit for people with Parkinson’s.
Celebrating neuroscience in spring 2023
We are partnering with the British Neuroscience Association (BNA) to plan and deliver the BNA International Festival of Neuroscience 2023.
Parkinson’s UK celebrity ambassador David ‘Kid’ Jensen takes part in world-first clinical trial
Broadcasting legend and Parkinson's UK celebrity ambassador David ‘Kid’ Jensen is taking part in a world-first clinical trial. The trial will help researchers understand if an anti-sickness drug could treat hallucinations in people with Parkinson’s or Lewy body dementia.
Understanding symptoms early after Parkinson’s diagnosis
An important research partnership involving Parkinson’s UK, pharmaceutical company UCB and the Parkinson’s Foundation has published their first results in a study designed alongside people living with Parkinson’s.
Progress towards Apple Watch based tracking of symptoms
An app that links to Apple Watch technology has been granted FDA approval to help monitor some motor symptoms experienced by people with Parkinson’s.
Save Parkinson’s clinical research. Take part today
We’re calling on the Parkinson’s community to take part in 5 important clinical studies that are currently at risk of closure.
NRG Therapeutics awarded £2.68m to develop treatments that could slow Parkinson's
Biotech company, NRG Therapeutics, has today announced an Innovate UK award to continue its drug development project, supported by the Parkinson's Virtual Biotech, into life-changing new treatments.